Stabilized Enzymes Or Enzymes Complexed With Nonenzyme (e.g., Liposomes, Etc.) Patents (Class 424/94.3)
-
Publication number: 20140377243Abstract: The present invention relates to a cell permeable fusion protein for strengthening regenerative potential of stem cells, and more particularly to a cell permeable fusion protein for strengthening regenerative potential of stem cells for stimulating the differentiation of stem cells, inhibiting apoptosis, maintaining the functionality of stem cells and restoring the stress-inhibited functionality of stem cells.Type: ApplicationFiled: December 16, 2011Publication date: December 25, 2014Applicants: NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO, LTD., SEOUL NATIONAL UNIVERSITY R AND DB FOUNDATIONInventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee
-
Publication number: 20140377215Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: ApplicationFiled: December 14, 2012Publication date: December 25, 2014Applicant: The Board of Trustees of the University of ArkansaInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
-
Publication number: 20140369987Abstract: The invention relates to the use of peptides corresponding to dermaseptin B2 or fragments thereof for treating proliferative diseases such as cancer or ocular lesions, and to pharmaceutical compositions containing such peptides.Type: ApplicationFiled: August 29, 2014Publication date: December 18, 2014Inventors: Jean DELBE, Mohamed AMICHE, Ali LADRAM, Cecile GALANTH, Pierre NICOLAS, Yamina HAMMA, Johanna Allegonda Anna VAN ZOGGEL, Jose COURTY
-
Publication number: 20140369986Abstract: The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.Type: ApplicationFiled: May 15, 2014Publication date: December 18, 2014Applicant: GangaGen, Inc.Inventors: Sriram Padmanabhan, Vivek Daniel Paul, R.Sanjeev Saravanan, Bharathi Sriram
-
Publication number: 20140369960Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via an amine group; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two amine groups; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via amine groups in saiType: ApplicationFiled: July 28, 2014Publication date: December 18, 2014Inventors: Stephen James BROCCHINI, Antony Robert Godwin, Elisa Pedone, Ji-Won Choi, Sunil Shaunak
-
Patent number: 8906379Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: January 20, 2012Date of Patent: December 9, 2014Assignee: Genzyme CorporationInventor: James Stefano
-
Patent number: 8894993Abstract: The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q10 (CoQ10), reduced CoQ10, or mixtures thereof and oxygenated dibenzo-?-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and/or provide therapy to individuals at risk and/or under treatment for dysfunctions of energy metabolism, and specifically, for mitochondrial diseases.Type: GrantFiled: July 27, 2007Date of Patent: November 25, 2014Assignees: Natreon Inc., Indian Herbs Research & Supply Company, Ltd.Inventor: Shibnath Ghosal
-
Patent number: 8889398Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.Type: GrantFiled: May 18, 2007Date of Patent: November 18, 2014Assignee: Viroblock SAInventors: Thierry Pelet, Francesca A. Wallach
-
Publication number: 20140335163Abstract: The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.Type: ApplicationFiled: November 30, 2012Publication date: November 13, 2014Inventors: Dominique Boivin, Jean-Paul Castaigne, Michel Demeule, Sasmita Tripathy, Jean-Christophe Currie, Simon Lord-Dufour
-
Patent number: 8883141Abstract: A hydrolytic enzyme is stabilized in a liquid surfactant preparation using a component that stabilizes the hydrolytic enzyme and includes a phenylalkyldicarboxylic acid.Type: GrantFiled: January 25, 2013Date of Patent: November 11, 2014Assignee: Henkel AG & Co. KGaAInventors: Petra Siegert, Marion Merkel, Hendrik Hellmuth, Timothy O'Connell, Karl-Heinz Maurer
-
Patent number: 8883140Abstract: A hydrolytic enzyme is stabilized in a liquid surfactant preparation using a component that stabilizes the hydrolytic enzyme and encompasses an oligoaminobiphenyl oligocarboxylic acid.Type: GrantFiled: January 25, 2013Date of Patent: November 11, 2014Assignee: Henkel AG & Co. KGaAInventors: Petra Siegert, Marion Merkel, Hendrik Hellmuth, Timothy O'Connell, Karl-Heinz Maurer
-
Publication number: 20140328819Abstract: The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.Type: ApplicationFiled: March 18, 2014Publication date: November 6, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Willem Peter Stemmer, Chia-Wei Wang, Benjamin Spink, Nathan Carl Geething, Wayne To
-
Publication number: 20140328820Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.Type: ApplicationFiled: May 12, 2014Publication date: November 6, 2014Applicant: Ansun Biopharma, Inc.Inventors: Fang Fang, Michael Malakhov
-
Patent number: 8877183Abstract: Methods and therapeutic treatments of ocular diseases are provided including applying peg-Arginase I to affected eyes. Methods are provided that simultaneously treat inflammation and neovascularization of eyes while promoting healing. Methods are provided to treat lesions or infections of an eye.Type: GrantFiled: March 14, 2013Date of Patent: November 4, 2014Assignees: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resources (DEITR)Inventors: Timothy Paul Foster, Paulo Cesar Rodriguez, James Milton Hill, Augusto Ochoa
-
Publication number: 20140322191Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: ApplicationFiled: May 1, 2014Publication date: October 30, 2014Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
-
Publication number: 20140308342Abstract: The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.Type: ApplicationFiled: November 7, 2012Publication date: October 16, 2014Inventors: David A. Spiegel, Charles E. Jakobsche
-
Publication number: 20140302122Abstract: The present invention relates to methods of reducing, delaying, preventing and/or inhibiting the progression of a Cryptococcus infection into the central nervous system (CNS) of a subject by inhibiting the activity of a M36 fungalysin metalloprotease (e.g., MPR1) secreted by the Cryptococcus. The invention further provides methods of increasing, promoting and/or enhancing delivery of a therapeutic agent across the blood-brain-barrier, comprising systemically administering the therapeutic agent in conjunction with a M36 fungalysin metalloprotease (e.g., MPR1), or an enzymatically active fragment thereof.Type: ApplicationFiled: September 7, 2012Publication date: October 9, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Angela C. Gelli
-
Publication number: 20140302001Abstract: Described herein are methods of making targeting peptides conjugated to recombinant lysosomal enzymes by modifying the amino (N)-terminus and one or more lysine residues on recombinant human lysosomal enzymes using a first crosslinking agent to give rise to first crosslinking agent modified recombinant human lysosomal enzymes, modifying the first amino acid within a short linker at the amino (N)-terminus on a variant IGF-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short linker. Also described herein are conjugates synthesized characterized as having higher affinities for the IGF2/CI-MPR receptor and cellular uptake using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.Type: ApplicationFiled: May 25, 2012Publication date: October 9, 2014Applicant: Callidus Biopharma, Inc.Inventor: Hung Do
-
Publication number: 20140294762Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: April 7, 2014Publication date: October 2, 2014Applicant: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn L. Bowe, Xi Chen
-
Publication number: 20140294797Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.Type: ApplicationFiled: June 10, 2014Publication date: October 2, 2014Inventors: Keith FOSTER, John CHADDOCK, Charles PENN, Kei Roger AOKI, Joseph FRANCIS, Lance STEWARD
-
Patent number: 8846603Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: GrantFiled: March 11, 2011Date of Patent: September 30, 2014Assignee: Synageva Biopharma Corp.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20140286925Abstract: The present invention relates to polypeptides for use in suppressing cancer and cancer disorders. The treatment employs use of a non-cytotoxic protease, which is targeted to the cancer cell, and, when so delivered, the protease is internalised and inhibits secretion from the cancer cell.Type: ApplicationFiled: June 4, 2014Publication date: September 25, 2014Applicant: Syntaxin LimitedInventors: Frederic MADEC, Philip LECANE, Philip MARKS, Keith FOSTER
-
Publication number: 20140271640Abstract: The present disclosure provides complexes comprising an FGF-10 portion and a heterologous protein or peptide, as well as methods of using such complexes.Type: ApplicationFiled: December 6, 2013Publication date: September 18, 2014Applicant: PERMEON BIOLOGICS, INC.Inventors: Katherine S. Bowdish, Erik M. Vogan, John F. Ross, Ann Dewitt
-
Publication number: 20140271598Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.Type: ApplicationFiled: August 23, 2013Publication date: September 18, 2014Applicant: Shire Human Genetic Therapies, Inc.Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Rick Fahrner, Jing Pan, Teresa Leah Wright, Pericles Calias
-
Patent number: 8834865Abstract: The invention provides methods, compositions, systems, and kits that include an enzyme/substrate co-delivery system. The liquid delivery system includes at least one enzyme encapsulated in a water-soluble polymeric matrix and a substrate for the enzyme in a carrier liquid in which the polymeric matrix is insoluble. When water is added, the polymeric matrix is solubilized and enzyme is released from the matrix, permitting catalytic action upon the substrate.Type: GrantFiled: November 3, 2009Date of Patent: September 16, 2014Assignee: Danisco US Inc.Inventors: Nathaniel T. Becker, Michael Stoner, Mee-Young Yoon
-
Patent number: 8834866Abstract: The present invention provides chimeric polypeptides comprising myotubularin 1 (MTMI) polypeptides and an internalising moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a fragment thereof. One aspect of the present invention provides compositions comprising these chimeric polypeptides together with a pharmaceutically acceptable carrier, and optionally, a further therapeutic agent. Another aspect of the present invention provides methods of treating Myotubular Myopathy comprising administering the polypeptides or compositions comprising the polypeptides to a subject in need.Type: GrantFiled: June 15, 2010Date of Patent: September 16, 2014Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Publication number: 20140255378Abstract: The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.Type: ApplicationFiled: August 8, 2012Publication date: September 11, 2014Applicant: aTyr Pharma, IncInventors: Jeffrey D. Watkins, Ying Ji Buechler, Chi-Fang Wu, Minh-Ha Do, Alain P. Vasserot, John D. Mendlein
-
Publication number: 20140255309Abstract: A peptide for synthesizing silica and use thereof are provided. The peptide for synthesizing silica can polymerize silica from a silica precursor in an aqueous solution having conditions of normal temperature, normal pressure and near-neutral weak base. The peptide for synthesizing silica can form a self-assembled structure during silica synthesis, and thus can be used as various biomaterials such as a silica-based protein immobilizer, a biosensor, and a drug delivery system.Type: ApplicationFiled: October 2, 2012Publication date: September 11, 2014Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventors: Seung Pil Pack, Mi Ran Ki
-
Publication number: 20140255375Abstract: Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia.Type: ApplicationFiled: February 13, 2014Publication date: September 11, 2014Applicant: aTyr Pharma, Inc.Inventors: Rajesh Belani, Jeffry Dean Watkins, Wei Zhang, Alain Phillippe Vasserot
-
Publication number: 20140255377Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicant: Vision Global Holdings Ltd.Inventors: Bing Lou WONG, Norman Fung Man WAI, Sui Yi KWOK, Yun Chung LEUNG
-
Publication number: 20140255374Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.Type: ApplicationFiled: November 6, 2013Publication date: September 11, 2014Applicant: CERULEAN PHARMA INC.Inventor: Scott Eliasof
-
Publication number: 20140255376Abstract: A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.Type: ApplicationFiled: February 14, 2014Publication date: September 11, 2014Inventors: Eric A. Johnson, Sabine Pellett, William H. Tepp, Tony L. Yaksh, Marc Marino, Qinghao Xu
-
Publication number: 20140248237Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: ApplicationFiled: May 7, 2014Publication date: September 4, 2014Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Publication number: 20140242056Abstract: There is provided a method of producing a stabilized catalase enzyme. In the method, a substrate is thoroughly mixed with phosphate borate and catalase, rinsed with water and the solids dried. The dried solid may be mixed with polyvinyl alcohol and dried for further stabilization. The stabilized powder may be mixed with various skin solutions (lotions, ointments and the like). The catalase enzyme can catalyze the reaction of peroxide to oxygen.Type: ApplicationFiled: February 21, 2014Publication date: August 28, 2014Applicant: Kimberly-Clark Worldwide, Inc.Inventors: Bhalchandra M. Karandikar, Sunita J. Macwana, Zhongju Liu Zhao
-
Publication number: 20140242057Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Applicant: Novo Nordisk A/SInventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
-
Publication number: 20140227260Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 21, 2014Publication date: August 14, 2014Applicant: Auspex Pharmaceuticals, Inc.Inventor: Chengzhi Zhang
-
Publication number: 20140227350Abstract: The use of tPA to treat hemorrhagic transformation, neurotoxicity has been limited to short treatment time windows because a high dose of tPA required to generate sufficient amounts of the enzyme plasmin for clot lysis. The present invention combines tPA with recombinant Annexin A2 resulting in thrombolysis without hemorrhagic transformation at delayed times after stroke. This embodiment allows the administration of a lower, non-neurotoxic, tPA dose. Our results suggest this novel combination for stroke therapy may greatly improve both efficacy and safety, and prolong tPA therapeutic time window.Type: ApplicationFiled: March 5, 2014Publication date: August 14, 2014Inventors: Xiaoying Wang, Eng Lo
-
Publication number: 20140227185Abstract: The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs. Thereto, the compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to glutathione-based ligands that facilitate the specific binding to and internalization by these glutathione transporters.Type: ApplicationFiled: March 18, 2014Publication date: August 14, 2014Applicant: TO-BBB HOLDING B.V.Inventor: Pieter Jaap GAILLARD
-
Patent number: 8802087Abstract: Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.Type: GrantFiled: March 22, 2005Date of Patent: August 12, 2014Assignee: Abbott Products GmbHInventors: George Shlieout, Bernd Boedecker, Siegfried Schaefer, Bernd Thumbeck, Peter-Colin Gregory
-
Publication number: 20140219983Abstract: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: Syntaxin LimitedInventors: Frederic MADEC, Phil LECANE, Philip MARKS, Keith FOSTER
-
Patent number: 8795734Abstract: Methods and materials for delivering biologically active molecules to cells in vitro or in vivo are provided. The methods and materials use carbon nanotubes or other hydrophobic particles, tubes and wires, functionalized with a linking group that is covalently bound to the nanotubes, or, alternatively, to the biologically active molecule, such as a protein. The biologically active molecule is preferably released from the nanotube when the complex has been taken up in an endosome.Type: GrantFiled: August 3, 2012Date of Patent: August 5, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Hongjie Dai, Nadine Wong Shi Kam, Paul A. Wender, Zhuang Liu
-
Publication number: 20140212403Abstract: The invention provides reagents and methods for enzyme replacement therapy using chemically modified species of human cystathionine ?-synthase (CBS) to treat homocystinuria and other related diseases and disorders.Type: ApplicationFiled: March 14, 2013Publication date: July 31, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: Jan P KRAUS, Thomas MAJTAN, Erez BUBLIL
-
Patent number: 8790639Abstract: Peptidoglycan hydrolases are an effective new source of antimicrobials. A chimeric fusion protein of the Ply187 endopeptidase domain and LysK SH3b cell wall binding domain is a potent agent against Staphylococcus aureus in three functional assays.Type: GrantFiled: March 28, 2012Date of Patent: July 29, 2014Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: David M. Donovan, Jinzhe Mao
-
Publication number: 20140205583Abstract: This invention relates to methods of modifying pyridoxal 5? phosphate (PLP) dependent enzymes to extend the serum half-life of the enzyme, extend the in vivo period of methionine depletion in a host, and decrease the immunogenicity of the enzyme. A preferred PLP-dependent enzyme to be modified is a methioninase, preferably a recombinant methioninase (rMETase). The invention further relates to compositions comprising a modified PLP-dependent enzyme and methods of using the same.Type: ApplicationFiled: January 23, 2014Publication date: July 24, 2014Applicant: ANTICANCER, INC.Inventors: Shigeo YAGI, Zhijian YANG, Shukuan LI, Xinghua SUN, Yuying TAN
-
Patent number: 8785595Abstract: Reagents and methods for functionalizing polypeptides with moieties poly (alkylene glycol) molecules and glycan groups are disclosed that are based on a functionalizing reagent which comprises a nitrogen containing heterocyclic aromatic ring having a vinyl substituent that is capable of reacting with one or more thiol groups that are naturally present, or have been introduced into, the polypeptide, for example by employing a thiol group of one or more cysteine residues. The functionalizing reagent is covalently linked to a poly (alkylene glycol) molecule, such as a polyethylene glycol (PEG) molecule, or a glycan group so that the reaction between the vinyl group and the thiol group in the polypeptide covalently links the polypeptide to the poly (alkylene glycol) molecule and/or the glycan group.Type: GrantFiled: December 21, 2009Date of Patent: July 22, 2014Assignee: Glythera LimitedInventors: Andrew Graham Watts, Terrence Kantner, Amanda Barbara MacKenzie
-
Publication number: 20140199283Abstract: The present invention provides an aqueous pharmaceutical composition comprising the fusion protein whose amino acid sequence is set forth as SEQ ID No:1 and an aqueous solution comprising 40 to 60 mM sodium phosphate. The present invention further provides a lyophilized pharmaceutical composition, an reconstituted solution, a sealed package comprising the lyophilized pharmaceutical composition, and a vial comprising the lyophilized pharmaceutical or the reconstituted solution. The present invention also provides a method of producing the lyophilized pharmaceutical composition and the sealed package. The present invention also provides a method of treating a human having cocaine seeking behavior, and methods of using the aqueous pharmaceutical composition and lyophilized pharmaceutical composition.Type: ApplicationFiled: January 14, 2014Publication date: July 17, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Qinghai Zhao, Xia Luo, Jason Bock
-
Publication number: 20140199282Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.Type: ApplicationFiled: February 26, 2014Publication date: July 17, 2014Inventors: Louis Bookbinder, Anirban Kundu, Gregory I. Frost
-
Patent number: 8778336Abstract: Disclosed is an invention which relates to synthesizing immobilized and crosslinked proteases derived from plants for use as skin care agents. The resulting stabilized protease will minimally penetrate the skin because of its immobilized nature. It will retain activity because of its crosslinked nature and, in certain embodiments, due to its stabilization via physical additives. The present invention relates in particular to a linked papain product used in topical skin applications.Type: GrantFiled: January 19, 2011Date of Patent: July 15, 2014Assignee: BASF CorporationInventor: Manasi Chavan
-
Publication number: 20140193425Abstract: Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALK1 agonist, e.g., an ALK1 ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALK1 antagonist are also provided.Type: ApplicationFiled: October 4, 2013Publication date: July 10, 2014Applicant: Acceleron Pharma, Inc.Inventors: John Knopf, Ravindra Kumar, Robert S. Pearsall, Matthew L. Sherman
-
Publication number: 20140193358Abstract: The disclosure provides targeted cargo proteins that are useful for targeting cancer stem cells, and methods of their use in treating cancer.Type: ApplicationFiled: October 4, 2013Publication date: July 10, 2014Applicant: PROTOX THERAPEUTICS, INC.Inventor: Fahar Merchant